Previous 10 | Next 10 |
Recursion Pharma is hoping to revolutionize drug discovery with its Recursion OS technology; potential to improve drug discovery and processing capabilities. Recent deal with Roche brought in an upfront payment of $150 million, with potential to earn up to $300 million for each of the...
Calliditas Therapeutics (NASDAQ:CALT) +67%. Recursion Pharmaceuticals (NASDAQ:RXRX) +10%. Verrica Pharmaceuticals (NASDAQ:VRCA) +9%. Qorvo (NASDAQ:QRVO) +6%. Sharecare (NASDAQ:SHCR) +5%. Blue Bird (NASDAQ:BLBD) -10%. Freshworks (NASDAQ:FRSH) -4%. Nutanix (NASDAQ:NTNX) -4%. Cumberland Pharmace...
A monoclonal antibody under development from Roche (OTCQX:RHHBY) company Genentech was granted Orphan Drug designation for spinal muscular atrophy. The treatment is classified as a recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH dependen...
The European Medicines Agency ("EMA") has approved Roche's (OTCQX:RHHBY +0.1%) COVID-19 antibody treatment Actemra/RoActemra (tocilizumab). The regulator's Committee for Medicinal Products for Human Use recommended approval yesterday. The therapy is approved for adults receiving systemic cort...
Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology The deal, worth several billion dollars, is a...
Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities Use of latest Recursion inference technologies to expand exploration of fibrosis and may extend the collaboration to more than a dozen programs in total Recursion's powerful inferent...
Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Senior Appointments Appointments will support continued expansion in neuroscience and acceleration of inferential search capabilities Tim Ahfeldt, Ph.D., Irit Rappley, Ph.D. and Glenn Morriso...
Narrow AI is trained to solve problems and adapt to change using the concept of machine learning. AI algorithms analyse previous actions and can autonomously improve when given new datasets. AI can analyse vast quantities of data, allowing it to identify patterns in datasets that are ...
Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) sank 17.7% lower as of the market close on Wednesday. The decline came after the company provided its third-quarter update Wednesday morning. Recursion reported revenue in the third quarter of $2.5 million, up 147% year over yea...
Recursion Pharmaceuticals (NASDAQ:RXRX): Q3 GAAP EPS of -$0.28 in-line. Revenue of $2.53M (+148.0% Y/Y) misses by $0.17M. Press Release For further details see: Recursion Pharmaceuticals EPS in-line, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
Recursion Pharmaceuticals Inc. Company Name:
RXRX Stock Symbol:
NASDAQ Market:
Recursion Pharmaceuticals Inc. Website:
2024-07-27 05:41:00 ET Investors looking for stocks that can make dramatic gains often turn toward the biotechnology sector. It isn't unusual for stocks in this industry to shoot higher in response to positive clinical-trial results for experimental new drugs. Recursion Pharmaceutical...
2024-07-13 09:29:00 ET Recursion Pharmaceuticals (NASDAQ: RXRX) is arguably one of the most unique drugmakers on the planet. Though it's classified as a biotech company, its claim to fame is an artificial intelligence (AI)-based approach to speeding up drug discovery and development...
2024-07-11 10:10:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmac...